Skip to content

Invest in a Cure for Diabetes

Regenerative Medical Solutions is looking for venture capitalists and biotech investors to help fund its medical research.

About Our Work

If you’re looking for biotech companies to invest in, RMS stands out from the crowd. Our potential cure for diabetes is an unparalleled solution that eliminates the need for heavy immunosuppressive drugs, works for all blood types, and does not use embryos. We see huge success for our solution, which removes the risk of complications and side effects that are so often seen with other cures that rely on the success of anti-rejection drugs.  We offer the opportunity to be part of something truly innovative that will enable millions of people to live happier and healthier lives.

Your Biotech Investment Opportunity

Our new technology offers the perfect opportunity for anyone looking to invest in biotech. Whether you’re an individual interested in biotech investing or part of a venture capital group, we encourage you to get in touch.

If you’re new to investing in biotech, it’s a great place to start. Our team of scientists is located in Madison and we’re available to discuss investment opportunities, the return on investment potential, and the goals we’ll reach together.

You can help work towards a cure if you choose Regenerative Medical Solutions as your next biotech investment opportunity.

Contact Us About Biotech Investing

We encourage biotech investment groups and individual venture capitalists to get in touch and learn more about what makes RMS one of the best biotech companies to invest in.

Call today or fill out the form below to learn more about our biotech investment opportunities and receive additional investor materials.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Frequently Asked Questions

To help you discern whether Regenerative Medical Solutions offers the right biotech investment opportunity for you, here are some answers to questions we often receive.

We are at the stage of preparing an IND (Investigational New Drug) submission; we’re on the cusp of starting human clinical trials.

Regenerative Medical Solutions has the best team in the industry. Dr. Jon Odorico is the Scientific Founder of RMS and is known for his research and practical experience in the field.

Dr. Odorico is a revered Professor in the Department of Surgery, Division of Organ Transplantation, at the University of Wisconsin-Madison School of Medicine and Public Health.

Additionally, he is certified by the American Board of Surgery and has vast experience completing pancreas transplants, islet cell transplants, multi-organ transplants, and more surgical procedures.

On our Leadership page, you can learn more about Dr. Odorico, the numerous awards he has won, and the publications he has contributed to.

Our Scientific Founder, Dr. Odorico, played a key role in the first isolation and culturing of stem cells in the mid-1990s at the University of Wisconsin-Madison. This work was hailed as a major scientific breakthrough and featured on the cover of Time Magazine. 

Additionally, Dr. Odorico is a successful pancreatic and islet transplant surgeon with over 25 years of experience curing people with diabetes using cadaver islets. Cadaver islets come from human donors, so there are not enough islets available to treat every patient. Unfortunately, this existing process also requires the use of immunosuppressants; our new prospective cure does not have either of these limitations, and this existing method acts as proof of concept for our new technology. We believe our team and experience make RMS a great option for anyone looking to invest in biotech.

Competitors are working on similar cures for diabetes, but the current clinical competitor requires the patient to take anti-rejection drugs, which can lead to complications. The side effects of taking anti-rejection drugs range from headaches to gastrointestinal issues, osteoporosis, an increased risk of developing cancer, and even potential complications leading to death.

Yes, we plan to be acquired by a major pharmaceutical company once an initial Phase I human clinical trial is complete, if not before. An equivalent biotech company was recently bought for approximately $950 million at a similar stage of development as RMS is now. That competitive company was acquired before any human studies were initiated. We understand that investors need to keep exit strategies in mind when looking for biotech companies to invest in and are happy to discuss this further.

Headquarters:
505 S Rosa Road, Suite 26,
Madison, WI 53719

Billing Address:
8770 W Bryn Mawr Avenue, Ste 1300,
Chicago, IL 60631

Phone: 312-725-6450
Email: info@regenmedsolutions.com